This review examines real-world evidence showing semaglutide, liraglutide, and tirzepatide are effective for obesity treatment outside clinical trials, while highlighting major affordability and access challenges.
3 approved peptide-based obesity drugs reviewedSemaglutide, liraglutide, and tirzepatide all show real-world effectiveness for obesity, but their high cost prevents most eligible patients from accessing them.
What the researchers found
The review confirms that semaglutide, liraglutide, and tirzepatide demonstrate meaningful weight reduction in real-world settings, consistent with clinical trial results. All three agents show pleiotropic (multi-system) benefits beyond weight loss, including cardiovascular and metabolic improvements. However, the high cost of these medications remains a significant barrier to widespread adoption. Real-world evidence suggests that while efficacy is maintained outside trial settings, affordability and access limitations prevent these drugs from reaching the majority of people who could benefit.
Why it matters
Clinical trials show what a drug can do under ideal conditions; real-world evidence shows what it actually does in routine practice with diverse patient populations. This review bridges that gap for the three most important obesity medications available today. The affordability question is equally critical — even the most effective drug can't address a global epidemic if most patients can't access it.
How the study worked
Narrative review article synthesizing published real-world evidence and cost-effectiveness data for approved GLP-1 receptor agonists (semaglutide, liraglutide) and the dual GIP/GLP-1 agonist tirzepatide in obesity treatment. The review focused on studies conducted outside randomized controlled trial settings to assess real-world effectiveness and economic feasibility.
What this study cannot tell us
As a narrative review, the methodology for study selection and synthesis is not as rigorous as a systematic review. The rapidly evolving pricing landscape and ongoing insurance coverage changes may make cost-effectiveness conclusions quickly outdated. Real-world evidence is inherently subject to selection bias and confounding. The review may not capture the most recent data given the fast pace of publication in this field.
How to read the evidence
This is a narrative review synthesizing real-world observational studies and cost-effectiveness analyses. While it provides a useful overview, it does not employ systematic review methodology and the quality of underlying evidence varies from study to study.
When this study was published
Published in 2024, this review captures the current state of real-world evidence for the three leading peptide-based obesity medications, including tirzepatide which received obesity approval relatively recently.
The bigger picture
The obesity treatment landscape has been transformed by GLP-1-based peptide drugs, but we're now entering a critical phase where the gap between drug efficacy and population access must be addressed. This review highlights a fundamental tension: revolutionary medications exist, but their cost prevents them from meaningfully denting obesity prevalence at the population level. How healthcare systems resolve this will shape public health outcomes for decades.
Questions still open
- What pricing or policy strategies could make GLP-1 agonists accessible enough to meaningfully reduce obesity prevalence?
- How do real-world discontinuation rates and weight regain compare across semaglutide, liraglutide, and tirzepatide?
- Could biosimilar or generic versions of these peptide drugs eventually solve the affordability problem?
Common questions
Do obesity drugs like semaglutide and tirzepatide work as well in real life as in clinical trials?
Why aren't more people using these obesity medications?
Read the original research
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.
Pragmatic and observational research, 15, 139-149
Citation
Patoulias, Dimitrios; Koufakis, Theocharis; Ruža, Ieva; El-Tanani, Mohamed; Rizzo, Manfredi. (2024). Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.. Pragmatic and observational research, 15, 139-149. https://doi.org/10.2147/POR.S471476